Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy and Safety of DLBS3233 in Adults With Prediabetes
Sponsor: Dexa Medica Group
Summary
This is a 3-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing DLBS3233 at a dose of 100 mg once daily; DLBS3233 at a dose of 200 mg once daily; and Metformin XR 500 mg twice daily for a 12-week course of therapy. DLBS3233 is a bioactive fraction derived from a combination of Lagerstroemia speciosa and Cinnamomum burmanii. DLBS3233 exhibits antidiabetic properties by enhancing insulin signaling, improving glucose uptake, modulating lipid metabolism, and reducing insulin resistance.
Official title: A Randomized, Double-Blind, Parallel, Controlled, Non-Inferiority Study to Evaluate the Efficacy and Safety of DLBS3233 in Adults With Prediabetes
Key Details
Gender
FEMALE
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-07-07
Completion Date
2026-10-15
Last Updated
2026-11-16
Healthy Volunteers
No
Conditions
Interventions
DLBS3233
DLBS3233 will be given into two different groups; 1 capsule of DLBS3233 100 mg once daily and 2 capsules of DLBS3233 100 mg once daily.
Metformin XR
Metformin XR 500 mg will be given 1 tablet twice daily as a comparator.
Locations (2)
Department of Internal Medicine, Dr. Soetomo Regional Public Hospital
Surabaya, East Java, Indonesia
Equilab International
Jakarta, Jakarta Special Capital Region, Indonesia